Download PDF
Semin Liver Dis 2023; 43(02): 133-141
DOI: 10.1055/a-2082-5203
Review Article

Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting

Esteban Urias
1   Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
,
Vincent L. Chen
2   Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
› Author Affiliations
Funding V.L.C. was supported in part by NIDDK (K08 DK132312).
› Further Information
   Permissions and Reprints


Abstract

While nonalcoholic fatty liver disease is a leading cause of end-stage liver disease, most patients with nonalcoholic fatty liver disease do not develop cirrhosis and its complications. Therefore, risk stratification using inexpensive, noninvasive screening modalities is critical to avoid overdiagnosis and overtreatment of a large proportion of the population. In this review, we discuss the data supporting screening and current professional society recommendations on this topic. Screening for at-risk nonalcoholic fatty liver disease is recommended in patients with risk factors including diabetes, the metabolic syndrome, hepatic steatosis, and elevated aminotransferases. Screening typically consists of noninvasive testing using serum biomarkers followed by elastography using specialized imaging modalities. This sequential screening approach accurately identifies both high- and low-risk patients and is cost-effective when applied to at-risk populations. In conclusion, screening for advanced nonalcoholic fatty liver disease in the primary care setting is a crucial part of identifying high-risk patients who may benefit from aggressive intervention while avoiding overtreatment of patients at low risk of liver-related complications.

Keywords

noninvasive tests - NIT - advanced fibrosis - cirrhosis - NASH

Authors' Contribution

E.U. and V.L.C. contributed to the drafting and critical review of the manuscript.




Publication History

Accepted Manuscript online:
27 April 2023

Article published online:
16 May 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77 (05) 1797-1835
    CrossrefPubMedSearch in Google Scholar
  • 2 Kim BK, Tamaki N, Imajo K. et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol 2022; 77 (06) 1482-1490
    CrossrefPubMedSearch in Google Scholar
  • 3 Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of nonalcoholic fatty liver disease and hepatic fibrosis among US adults with prediabetes and diabetes, NHANES 2017-2018. J Gen Intern Med 2022; 37 (01) 261-263
    CrossrefPubMedSearch in Google Scholar
  • 4 Riazi K, Azhari H, Charette JH. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022; 7 (09) 851-861
    CrossrefPubMedSearch in Google Scholar
  • 5 Marengo A, Jouness RI, Bugianesi E. Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis 2016; 20 (02) 313-324
    CrossrefPubMedSearch in Google Scholar
  • 6 Ng CH, Xiao J, Lim WH. et al. Placebo effect on progression and regression in NASH: evidence from a meta-analysis. Hepatology 2022; 75 (06) 1647-1661
    CrossrefPubMedSearch in Google Scholar
  • 7 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13 (04) 643-54.e1 , 9, quiz e39–e40
    CrossrefPubMedSearch in Google Scholar
  • 8 Mantovani A, Csermely A, Petracca G. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6 (11) 903-913
    CrossrefPubMedSearch in Google Scholar
  • 9 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020; 111S: 154170
    CrossrefPubMedSearch in Google Scholar
  • 10 Angulo P, Kleiner DE, Dam-Larsen S. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149 (02) 389-97.e10
    CrossrefPubMedSearch in Google Scholar
  • 11 Ekstedt M, Hagström H, Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (05) 1547-1554
    CrossrefPubMedSearch in Google Scholar
  • 12 Ng CH, Lim WH, Hui Lim GE. et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023; 21 (04) 931-939.e5
    CrossrefPubMedSearch in Google Scholar
  • 13 Sanyal AJ, Van Natta ML, Clark J. et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385 (17) 1559-1569
    CrossrefPubMedSearch in Google Scholar
  • 14 Mangla N, Ajmera VH, Caussy C. et al. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2020; 18 (03) 744-746.e1
    CrossrefPubMedSearch in Google Scholar
  • 15 Jung J, Loomba RR, Imajo K. et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021; 70 (10) 1946-1953
    CrossrefPubMedSearch in Google Scholar
  • 16 Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med 2022; 292 (02) 190-204
    CrossrefPubMedSearch in Google Scholar
  • 17 Rowe IA, Wong VW, Loomba R. Treatment candidacy for pharmacologic therapies for NASH. Clin Gastroenterol Hepatol 2022; 20 (06) 1209-1217
    CrossrefPubMedSearch in Google Scholar
  • 18 Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017-2018. Clin Gastroenterol Hepatol 2021; 19 (07) 1499-1501.e2
    CrossrefPubMedSearch in Google Scholar
  • 19 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. J Intern Med 2020; 287 (06) 711-722
    CrossrefPubMedSearch in Google Scholar
  • 20 Sharma P, Arora A. Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. Transl Gastroenterol Hepatol 2020; 5: 19
    CrossrefPubMedSearch in Google Scholar
  • 21 National Guideline Centre. Non-Alcoholic Fatty Liver Disease: Assessment and Management. London: National Institute for Health and Care Excellence (NICE); 2016
    Search in Google Scholar
  • 22 European Association for the Study of the Liver (EASL), , European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
    CrossrefPubMedSearch in Google Scholar
  • 23 Kanwal F, Shubrook JH, Adams LA. et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021; 161 (05) 1657-1669
    CrossrefPubMedSearch in Google Scholar
  • 24 Wright AP, Desai AP, Bajpai S, King LY, Sahani DV, Corey KE. Gaps in recognition and evaluation of incidentally identified hepatic steatosis. Dig Dis Sci 2015; 60 (02) 333-338
    CrossrefPubMedSearch in Google Scholar
  • 25 Ekstedt M, Franzén LE, Mathiesen UL. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 (04) 865-873
    CrossrefPubMedSearch in Google Scholar
  • 26 Söderberg C, Stål P, Askling J. et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51 (02) 595-602
    CrossrefPubMedSearch in Google Scholar
  • 27 Newsome PN, Sasso M, Deeks JJ. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020; 5 (04) 362-373
    CrossrefPubMedSearch in Google Scholar
  • 28 Verhaegh P, Bavalia R, Winkens B, Masclee A, Jonkers D, Koek G. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018; 16 (06) 837-861
    CrossrefPubMedSearch in Google Scholar
  • 29 Natarajan Y, Kramer JR, Yu X. et al. Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes. Hepatology 2020; 72 (04) 1242-1252
    CrossrefPubMedSearch in Google Scholar
  • 30 ElSayed NA, Aleppo G, Aroda VR. et al; On Behalf of the American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care 2023; 46 (Suppl. 01) S49-S67
    CrossrefPubMedSearch in Google Scholar
  • 31 Doycheva I, Cui J, Nguyen P. et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 2016; 43 (01) 83-95
    CrossrefPubMedSearch in Google Scholar
  • 32 Lomonaco R, Godinez Leiva E, Bril F. et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 2021; 44 (02) 399-406
    CrossrefPubMedSearch in Google Scholar
  • 33 Ajmera V, Cepin S, Tesfai K. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 2023; 78 (03) 471-478
    CrossrefPubMedSearch in Google Scholar
  • 34 Loomba R, Wong R, Fraysse J. et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther 2020; 51 (11) 1149-1159
    CrossrefPubMedSearch in Google Scholar
  • 35 Chen VL, Oliveri A, Miller MJ. et al. PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology 2023; 164 (06) 966-977.e17
    CrossrefPubMedSearch in Google Scholar
  • 36 Kanwal F, Kramer JR, Li L. et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 2020; 71 (03) 808-819
    CrossrefPubMedSearch in Google Scholar
  • 37 Eslam M, Sarin SK, Wong VW. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020; 14 (06) 889-919
    CrossrefPubMedSearch in Google Scholar
  • 38 Bonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. J Hepatol 2009; 50 (01) 17-35
    CrossrefPubMedSearch in Google Scholar
  • 39 Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36 (5, Suppl 1): S57-S64
    PubMedSearch in Google Scholar
  • 40 Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53 (01) 325-335
    CrossrefPubMedSearch in Google Scholar
  • 41 Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med 2017; 377 (08) 756-768
    CrossrefPubMedSearch in Google Scholar
  • 42 Åberg F, Danford CJ, Thiele M. et al. A dynamic aspartate-to-alanine aminotransferase ratio provides valid predictions of incident severe liver disease. Hepatol Commun 2021; 5 (06) 1021-1035
    CrossrefPubMedSearch in Google Scholar
  • 43 Hagström H, Nasr P, Ekstedt M, Stål P, Hultcrantz R, Kechagias S. Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019; 17 (06) 1148-1156.e4
    CrossrefPubMedSearch in Google Scholar
  • 44 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59 (09) 1265-1269
    CrossrefPubMedSearch in Google Scholar
  • 45 Siddiqui MS, Yamada G, Vuppalanchi R. et al; NASH Clinical Research Network. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol 2019; 17 (09) 1877-1885.e5
    CrossrefPubMedSearch in Google Scholar
  • 46 Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 2017; 66 (01) 84-95
    CrossrefPubMedSearch in Google Scholar
  • 47 Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017; 66 (05) 1486-1501
    CrossrefPubMedSearch in Google Scholar
  • 48 McPherson S, Hardy T, Dufour JF. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017; 112 (05) 740-751
    CrossrefPubMedSearch in Google Scholar
  • 49 Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (10) 1104-1112
    CrossrefPubMedSearch in Google Scholar
  • 50 Loomba R, Harrison SA, Taub RA. et al. Utility of FIB-4, MRE, MRI-PDFF and FibroScan to identify patients with at-risk F2–F3 NASH based on screening data from a 2000 patient biopsy confirmed cohort of resmetirom phase 3 clinical trial, MAESTRO-NASH. In: The Liver Meeting AASLD. Washington; 2022
    PubMed
  • 51 Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013; 59 (02) 236-242
    CrossrefPubMedSearch in Google Scholar
  • 52 Vali Y, Lee J, Boursier J. et al; LITMUS Systematic Review Team. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 2020; 73 (02) 252-262
    CrossrefPubMedSearch in Google Scholar
  • 53 Day J, Patel P, Parkes J, Rosenberg W. Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis. J Appl Lab Med 2019; 3 (05) 815-826
    CrossrefPubMedSearch in Google Scholar
  • 54 Parkes J, Roderick P, Harris S. et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59 (09) 1245-1251
    CrossrefPubMedSearch in Google Scholar
  • 55 Eddowes PJ, Sasso M, Allison M. et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019; 156 (06) 1717-1730
    CrossrefPubMedSearch in Google Scholar
  • 56 Mózes FE, Lee JA, Selvaraj EA. et al; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022; 71 (05) 1006-1019
    CrossrefPubMedSearch in Google Scholar
  • 57 Papatheodoridi M, Hiriart JB, Lupsor-Platon M. et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol 2021; 74 (05) 1109-1116
    CrossrefPubMedSearch in Google Scholar
  • 58 Hsu C, Caussy C, Imajo K. et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 2019; 17 (04) 630-637.e8
    CrossrefPubMedSearch in Google Scholar
  • 59 Loomba R, Huang DQ, Sanyal AJ. et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut 2023; 72 (03) 581-589
    CrossrefPubMedSearch in Google Scholar
  • 60 Braude M, Roberts S, Majeed A. et al. Liver stiffness (FibroScan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. Liver Int 2023; 43 (01) 90-99
    CrossrefPubMedSearch in Google Scholar
  • 61 Boursier J, Hagström H, Ekstedt M. et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol 2022; 76 (05) 1013-1020
    CrossrefPubMedSearch in Google Scholar
  • 62 Ajmera V, Kim BK, Yang K. et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology 2022; 163 (04) 1079-1089.e5
    CrossrefPubMedSearch in Google Scholar
  • 63 Noureddin M, Truong E, Gornbein JA. et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol 2022; 76 (04) 781-787
    CrossrefPubMedSearch in Google Scholar
  • 64 Tamaki N, Imajo K, Sharpton SR. et al. Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD. Clin Gastroenterol Hepatol 2023; 21 (02) 380-387.e3
    CrossrefPubMedSearch in Google Scholar
  • 65 Ajmera V, Nguyen K, Tamaki N, Sharpton S, Bettencourt R, Loomba R. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2022;15:17562848221093869
    PubMed
  • 66 Sanyal AJ, Foucquier J, Younossi ZM. et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol 2023; 78 (02) 247-259
    CrossrefPubMedSearch in Google Scholar
  • 67 Nakatsuka T, Tateishi R, Sato M, Fujishiro M, Koike K. Agile scores are a good predictor of liver-related events in patients with NAFLD. J Hepatol 2023; S0168-8278 (23)00161-7
    CrossrefPubMedSearch in Google Scholar
  • 68 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis. Dig Dis Sci 2016; 61 (07) 2108-2117
    CrossrefPubMedSearch in Google Scholar
  • 69 Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME. NASHNET. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis. Gastroenterology 2020; 159 (05) 1985-1987.e4
    CrossrefPubMedSearch in Google Scholar
  • 70 Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. PLoS One 2016; 11 (02) e0147237
    CrossrefPubMedSearch in Google Scholar
  • 71 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol 2015; 25 (11) 3282-3294
    CrossrefPubMedSearch in Google Scholar
  • 72 Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol 2020; 73 (05) 1023-1029
    CrossrefPubMedSearch in Google Scholar
  • 73 Lee HW, Wong GL, Kwok R. et al. Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study. Hepatology 2020; 72 (04) 1230-1241
    CrossrefPubMedSearch in Google Scholar
  • 74 Udompap P, Therneau TM, Canning RE, Benson JT, Allen AM. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population. Hepatology 2023; 77 (03) 931-941
    CrossrefPubMedSearch in Google Scholar
  • 75 Xu X, Alanaeme J, Wen Y, Colantonio LD, Muntner P, Long MT. Real-world implications of the American Gastroenterology Association nonalcoholic fatty liver disease clinical care pathway in the US adult population. Gastroenterology 2023; 164 (04) 688-689.e4
    CrossrefPubMedSearch in Google Scholar
  • 76 Aggarwal P, Alkhouri N. Artificial intelligence in nonalcoholic fatty liver disease: a new frontier in diagnosis and treatment. Clin Liver Dis (Hoboken) 2021; 17 (06) 392-397
    CrossrefPubMedSearch in Google Scholar
  • 77 Kezer CA, Shah VH, Simonetto DA. Advances in predictive modeling using machine learning in the field of hepatology. Clin Liver Dis (Hoboken) 2021; 18 (06) 288-291
    CrossrefPubMedSearch in Google Scholar
  • 78 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep 2020; 2 (02) 100067
    CrossrefPubMedSearch in Google Scholar
  • 79 Miele L, De Michele T, Marrone G. et al. Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting. Int J Biol Markers 2017; 32 (04) e397-e402
    CrossrefPubMedSearch in Google Scholar
  • 80 Guha IN, Parkes J, Roderick P. et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47 (02) 455-460
    CrossrefPubMedSearch in Google Scholar